Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05701995 · ClinicalTrials.gov registry record · Phase 4

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

A Phase 4 study of Psoriasis, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 4
Development phase
180
Enrollment target
20
Study locations

NCT05701995 is a Phase 4 study of Psoriasis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 180 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05701995, a Phase 4 study of Psoriasis, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 4
Development phase
180 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.

Conditions Studied

Psoriasis

Interventions

  • OTHER Placebo
  • DRUG Deucravacitinib

Study Locations (20)

California

  • Local Institution - 0004 - Bakersfield
  • Local Institution - 0009 - Sacramento
  • Local Institution - 0022 - San Diego

Florida

  • Local Institution - 0027 - Brandon
  • Local Institution - 0016 - Coral Gables
  • Riverchase Dermatology - Pembroke Pines

Illinois

  • Local Institution - 0007 - Rolling Meadows
  • Local Institution - 0025 - Skokie
  • Local Institution - 0036 - Springfield

Arizona

  • Local Institution - 0006 - Phoenix
  • Local Institution - 0034 - Scottsdale

Georgia

  • Local Institution - 0037 - Atlanta
  • Local Institution - 0020 - Snellville

Michigan

  • Local Institution - 0010 - Auburn Hills
  • Local Institution - 0002 - Waterford

Arkansas

  • Local Institution - 0015 - North Little Rock

Colorado

  • Local Institution - 0030 - Centennial

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2023-01-31
Est. Completion 2025-05-29
Phase Phase 4

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05701995

The ClinicalTrials.gov registry entry for NCT05701995 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (63% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05701995 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT05701995 about?

NCT05701995 is a clinical study titled "A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting". The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.

What is the current status of trial NCT05701995?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2023-01-31. Estimated completion is 2025-05-29.

What conditions does trial NCT05701995 study?

This clinical trial studies the following conditions: Psoriasis.

What interventions are being tested in trial NCT05701995?

The interventions under investigation include: Placebo (OTHER), Deucravacitinib (DRUG).

Who is sponsoring clinical trial NCT05701995?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05701995 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Psoriasis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.